Skip to content

Study · Non-randomized trial · n = 45 · 2000

12 results

Long-term effects of growth hormone treatment on growth and puberty in patients with chronic renal insufficiency.

Hokken-Koelega A, Mulder P, De Jong R, Lilien M, Donckerwolcke R, Groothof J

Pediatric nephrology (Berlin, Germany)1 Jul 2000Cited by 53 (Europe PMC)

PMID10912546 (opens in a new tab)DOI10.1007/s004670000340 (opens in a new tab)PepBankPUB-10912546
Publisher pagePubMedAsk about this study
Jump to 12 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study12

12 results from studies that gave the peptide. 12 results from people.

  1. 01HumanNon-randomized trialSafety outcome

    In children with chronic renal insufficiency, no adverse effects of GH therapy were reported.

    In plain wordsIn children with chronic renal insufficiency, no adverse effects of GH therapy were reported.

    Peptide
    HGH (somatotropin)
    Outcome
    Not applicableAdverse effects
    Study

    n = 45

    Outcome group
    Adverse events · Whole body
    Studied dose
    Dose not stated

    Source sentences

    Summary
    GH therapy had no adverse effects or significant effect on parathyroid hormone concentration, nor were there any radiological signs of renal osteodystrophy.
    1 context sentence
    Summary · context
    Forty-five Dutch prepubertal children [28 boys, 17 girls, mean (SD) age 7.8 (3.4) years] with chronic renal insufficiency (CRI) and severe growth retardation started GH therapy between 1988 and 1991 within one of the randomized Dutch trials.
  2. 02HumanNon-randomized trialEfficacy outcome

    In children with chronic renal insufficiency, GH therapy had no significant effect on parathyroid hormone concentration.

    In plain wordsIn children with chronic renal insufficiency, parathyroid hormone concentration did not change significantly with GH therapy.

    Peptide
    HGH (somatotropin)
    Outcome
    No significant changeParathyroid hormone concentration
    Study

    n = 45

    Outcome group
    Bone and joint · Endocrine and hormones
    Studied dose
    Dose not stated

    Source sentences

    Summary
    GH therapy had no adverse effects or significant effect on parathyroid hormone concentration, nor were there any radiological signs of renal osteodystrophy.
    1 context sentence
    Summary · context
    Forty-five Dutch prepubertal children [28 boys, 17 girls, mean (SD) age 7.8 (3.4) years] with chronic renal insufficiency (CRI) and severe growth retardation started GH therapy between 1988 and 1991 within one of the randomized Dutch trials.
  3. 03HumanNon-randomized trialSafety outcome

    In children with chronic renal insufficiency receiving GH, no radiological signs of renal osteodystrophy were reported.

    In plain wordsIn children with chronic renal insufficiency receiving GH, no radiological signs of renal bone disease were reported.

    Peptide
    HGH (somatotropin)
    Outcome
    Not applicableRenal osteodystrophy signs
    Study

    n = 45

    Outcome group
    Bone and joint · Musculoskeletal
    Studied dose
    Dose not stated

    Source sentences

    Summary
    GH therapy had no adverse effects or significant effect on parathyroid hormone concentration, nor were there any radiological signs of renal osteodystrophy.
    1 context sentence
    Summary · context
    Forty-five Dutch prepubertal children [28 boys, 17 girls, mean (SD) age 7.8 (3.4) years] with chronic renal insufficiency (CRI) and severe growth retardation started GH therapy between 1988 and 1991 within one of the randomized Dutch trials.
  4. 04HumanObservational studyEfficacy outcome

    In children with chronic renal insufficiency, GH treatment for up to 8 years was linked to sustained height SDS improvement versus baseline (P<0.001).

    In plain wordsIn children with chronic renal insufficiency, GH treatment was linked to improved height SDS versus baseline.

    Peptide
    HGH (somatotropin)
    Outcome
    IncreaseHeight SDS over long-term treatment
    Study

    n = 45

    Outcome group
    Linear growth · Musculoskeletal
    Studied dose
    Dose not stated · maximum of 8 yearsAs given in this study (human).

    Source sentences

    Summary
    Long-term GH therapy, in this study a maximum of 8 years, resulted in a sustained and significant improvement of height standard deviation score (SDS) compared with baseline values (P<0.001).
    1 context sentence
    Summary · context
    Forty-five Dutch prepubertal children [28 boys, 17 girls, mean (SD) age 7.8 (3.4) years] with chronic renal insufficiency (CRI) and severe growth retardation started GH therapy between 1988 and 1991 within one of the randomized Dutch trials.
  5. 05HumanObservational studyEfficacy outcome

    In children with chronic renal insufficiency, mean height SDS reached -2 after 3 years of GH treatment.

    In plain wordsIn children with chronic renal insufficiency, mean height SDS reached -2 after 3 years of GH treatment.

    Peptide
    HGH (somatotropin)
    Outcome
    IncreaseHeight SDS after three years
    Study

    n = 45

    Outcome group
    Linear growth · Musculoskeletal
    Studied dose
    Dose not stated · 3 yearsAs given in this study (human).

    Measurements

    Mean height SDS
    ≈ −2 SDS
    after 3 years of GH therapy

    Source sentences

    Summary
    The mean height SDS reached the lower end (-2 SDS) of the normal growth chart after 3 years of GH therapy.
    1 context sentence
    Summary · context
    Forty-five Dutch prepubertal children [28 boys, 17 girls, mean (SD) age 7.8 (3.4) years] with chronic renal insufficiency (CRI) and severe growth retardation started GH therapy between 1988 and 1991 within one of the randomized Dutch trials.
  6. 06HumanObservational studyEfficacy outcome

    In children with chronic renal insufficiency, mean height SDS approached mean target height SDS after 6 years of GH treatment.

    In plain wordsIn children with chronic renal insufficiency, height SDS approached target height SDS after 6 years of GH treatment.

    Peptide
    HGH (somatotropin)
    Outcome
    IncreaseHeight SDS after six years
    Study

    n = 45

    Outcome group
    Linear growth · Musculoskeletal
    Studied dose
    Dose not stated · 6 yearsAs given in this study (human).

    Source sentences

    Summary
    During the following years the mean height SDS gradually increased, thereby approaching the mean target height SDS after 6 years of GH therapy.
    1 context sentence
    Summary · context
    Forty-five Dutch prepubertal children [28 boys, 17 girls, mean (SD) age 7.8 (3.4) years] with chronic renal insufficiency (CRI) and severe growth retardation started GH therapy between 1988 and 1991 within one of the randomized Dutch trials.
  7. 07HumanObservational studyEfficacy outcome

    In GH-treated children with chronic renal insufficiency, height SDS after 4 years related positively to initial height SDS and negatively to initial age and dialysis duration.

    In plain wordsIn GH-treated children with chronic renal insufficiency, height response was linked to initial height, age, and dialysis duration.

    Peptide
    HGH (somatotropin)
    Outcome
    MixedPredictors of height response
    Study

    n = 45

    Outcome group
    Linear growth · Musculoskeletal
    Studied dose
    Dose not stated · 4 yearsAs given in this study (human).

    Source sentences

    Summary
    Three factors were significantly associated with the height SDS after 4 years of GH therapy: height SDS at the start (+) of therapy, age at the start of therapy (-), and the duration of dialysis treatment (-).
    1 context sentence
    Summary · context
    Forty-five Dutch prepubertal children [28 boys, 17 girls, mean (SD) age 7.8 (3.4) years] with chronic renal insufficiency (CRI) and severe growth retardation started GH therapy between 1988 and 1991 within one of the randomized Dutch trials.
  8. 08HumanObservational studySafety outcome

    In children with chronic renal insufficiency, bone maturation did not accelerate during long-term GH treatment.

    In plain wordsIn children with chronic renal insufficiency, bone maturation did not accelerate during long-term GH treatment.

    Peptide
    HGH (somatotropin)
    Outcome
    No significant changeBone maturation
    Study

    n = 45

    Outcome group
    Bone and joint · Musculoskeletal
    Studied dose
    Dose not stated

    Source sentences

    Summary
    Bone maturation did not accelerate during long-term GH therapy.
    1 context sentence
    Summary · context
    Forty-five Dutch prepubertal children [28 boys, 17 girls, mean (SD) age 7.8 (3.4) years] with chronic renal insufficiency (CRI) and severe growth retardation started GH therapy between 1988 and 1991 within one of the randomized Dutch trials.
  9. 09HumanObservational studyEfficacy outcome

    In children with chronic renal insufficiency, average daily GH dose had no significant association with glomerular filtration rate after 4 years.

    In plain wordsIn children with chronic renal insufficiency, average GH dose had no significant link to kidney filtration after 4 years.

    Peptide
    HGH (somatotropin)
    Outcome
    No significant changeDose association with glomerular filtration rate
    Study

    n = 45

    Outcome group
    Kidney function · Kidney and urinary
    Studied dose
    Dose not stated · 4 yearsAs given in this study (human).

    Source sentences

    Summary
    The average daily GH dose administered over the years had no significant influence on the glomerular filtration rate after 4 years.
    1 context sentence
    Summary · context
    Forty-five Dutch prepubertal children [28 boys, 17 girls, mean (SD) age 7.8 (3.4) years] with chronic renal insufficiency (CRI) and severe growth retardation started GH therapy between 1988 and 1991 within one of the randomized Dutch trials.
  10. 10HumanObservational studySafety outcome

    In children initially on conservative renal treatment, renal function deterioration did not accelerate during 6 years of GH treatment.

    In plain wordsIn children initially on conservative renal treatment, kidney function deterioration did not accelerate during GH treatment.

    Peptide
    HGH (somatotropin)
    Outcome
    No significant changeRenal function deterioration
    Study

    n: not reported in source

    Outcome group
    Kidney function · Kidney and urinary
    Studied dose
    Dose not stated · 6 yearsAs given in this study (human).

    Source sentences

    Summary
    Children on a conservative regimen at the start of GH therapy had no accelerated deterioration of renal function during 6 years of GH therapy.
    1 context sentence
    Summary · context
    Forty-five Dutch prepubertal children [28 boys, 17 girls, mean (SD) age 7.8 (3.4) years] with chronic renal insufficiency (CRI) and severe growth retardation started GH therapy between 1988 and 1991 within one of the randomized Dutch trials.
  11. 11HumanObservational studyEfficacy outcome

    In GH-treated boys with chronic renal insufficiency, puberty began at a median age of 12.4 years, within the normal range.

    In plain wordsIn GH-treated boys with chronic renal insufficiency, puberty began at a median age of 12.4 years, within the normal range.

    Peptide
    HGH (somatotropin)
    Outcome
    Not applicablePuberty onset in boys
    Study

    n: not reported in source

    Outcome group
    Sex hormones and fertility · Reproductive and sexual health
    Studied dose
    Dose not stated

    Measurements

    Median age at puberty onset
    12.4 years
    boys with chronic renal insufficiency on GH

    Source sentences

    Summary
    Puberty started at a median age, within the normal range, of 12.4 years in boys and 12.0 years in girls, respectively.
    1 context sentence
    Summary · context
    Forty-five Dutch prepubertal children [28 boys, 17 girls, mean (SD) age 7.8 (3.4) years] with chronic renal insufficiency (CRI) and severe growth retardation started GH therapy between 1988 and 1991 within one of the randomized Dutch trials.
  12. 12HumanObservational studyEfficacy outcome

    In GH-treated girls with chronic renal insufficiency, puberty began at a median age of 12.0 years, within the normal range.

    In plain wordsIn GH-treated girls with chronic renal insufficiency, puberty began at a median age of 12.0 years, within the normal range.

    Peptide
    HGH (somatotropin)
    Outcome
    Not applicablePuberty onset in girls
    Study

    n: not reported in source

    Outcome group
    Sex hormones and fertility · Reproductive and sexual health
    Studied dose
    Dose not stated

    Measurements

    Median age at puberty onset
    12 years
    girls with chronic renal insufficiency on GH

    Source sentences

    Summary
    Puberty started at a median age, within the normal range, of 12.4 years in boys and 12.0 years in girls, respectively.
    1 context sentence
    Summary · context
    Forty-five Dutch prepubertal children [28 boys, 17 girls, mean (SD) age 7.8 (3.4) years] with chronic renal insufficiency (CRI) and severe growth retardation started GH therapy between 1988 and 1991 within one of the randomized Dutch trials.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    28 Oct 2026, 02:03 UTC

    Study results updated

  2. Version 1

    27 Oct 2026, 16:36 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.